Effect of statin therapy on disease progression in pediatric ADPKD: design and
baseline characteristics of participants.
Author(s): Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW.
Affiliation(s): Department of Medicine, University of Colorado Denver, Aurora, CO, USA.
Melissa.Cadnapaphornchai@ucdenver.edu
Publication date & source: 2011, Contemp Clin Trials. , 32(3):437-45
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic
kidney condition and is associated with important renal and cardiovascular
manifestations in childhood. Renal cystic disease can be documented in some cases
as early as in utero. Early intervention is critical if the long-term
complications of this condition, including end-stage renal disease, are to be
ameliorated. Here we describe our ongoing randomized double-blind
placebo-controlled phase III clinical trial to assess the effect of pravastatin
treatment on renal and cardiovascular disease progression in 107 children and
young adults age 8-22 years with ADPKD who are receiving the angiotensin
converting enzyme inhibitor lisinopril. Baseline demographic and laboratory data
are provided. Results of this study could markedly impact the standard of care
for evaluation and treatment of ADPKD in this population.
|